Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
PRNewswire - December 3, 2003
"Based on the excellent results we have seen in animal studies with mice, we have now moved our developmental program forward to non-human primates.
This step is consistent with our strategic plan and is the next phase in the validation of our Viral Immunotherapy platform," noted Dr. S. Lewis Meyer, President and CEO of Lipid Sciences. He continued, "The final results of these non-human primate studies will enable the Company to present data to the FDA (Food and Drug Administration) and discuss what additional pre-clinical animal testing, if any, might need to be completed before we move into a human clinical trial."
Lipid Sciences is a development-stage company engaged in the research and development of products and processes to treat major medical indications through its unique patented technology of lipid removal known as delipidation.
The Company's Viral Immunotherapy platform is focused on the removal of lipid coatings from viruses and other lipid-containing infectious agents by applications of its delipidation technology. It is believed that removing the agent's protective lipid coating exposes otherwise hidden viral proteins to stimulate the body's immune system and elicit an enhanced therapeutic response to the infectious agent. Conditions that can potentially be impacted by this technology include: HIV, Hepatitis B and Hepatitis C, West Nile and SARS.
The mouse studies were conducted under the direction of Dr. Aftab A. Ansari, Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine. Dr. Ansari is a member of the Lipid Sciences' Viral Advisory Board.
Dr. Ansari observed, "Lipid Sciences' delipidation process has resulted in a unique, optimized treatment that is highly effective, not only in delipidation, but also in reducing viral infectivity while appearing to retain a very high percentage of significant viral proteins. The delipidated virus has elicited an immune response against a distinct set of viral epitopes. The ability to respond to a broad array of antigens, exposed by the selective removal of the viral lipid coat, holds promise for the development of a novel autologous therapeutic vaccine for use in HIV patients."
The Viral Immunotherapy platform is just one of the technology platforms of Lipid Sciences. The Company's HDL therapy platform is aimed at developing potential treatments for the reversal of atherosclerosis, a disease of blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. If left untreated, these plaques are highly vulnerable to rupture and blood clot formation which can result in a fatal myocardial infarction (heart attack). Regression of such plaques may have a major impact on reducing the risk of acute coronary events. Lipid Sciences is researching and developing products and processes to treat major medical conditions in which lipids play a key role. The Company's HDL technology is based on a patented process that selectively and rapidly removes lipids from lipoproteins, such as HDL, without harming the proteins that carry the lipid particles. This HDL therapy has the ability to boost HDL efficiency in the reverse cholesterol transport system and the potential to reduce the risk of cardiovascular disease.
Lipid Sciences, Inc. is a development-stage biotechnology company that is researching and developing products and processes intended to treat major medical conditions in which lipids, or fat components, play a key role. The Company's technologies are based on a patented process that selectively removes lipids from proteins. The Company believes that this unique delipidation process has the potential for far-reaching implications related to human health. It may provide a therapeutic effect against many viral infections including HIV, Hepatitis B and Hepatitis C, SARS, and West Nile, among others, as well as reverse cardiovascular and cerebrovascular disease.
Forward-Looking Statements
This release contains forward-looking statements concerning plans, objectives, goals, strategies, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; our technology not proving to be safe or effective; our inability to obtain regulatory approval for our technology, which is only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International; our reliance on collaborations with strategic partners; competition in our industry; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; product liability claims; economic downturn in the real estate market; our dependence on key personnel; additional shares of common stock becoming available for sale after expiration of certain lock-up periods; and potential dilution of existing stockholders' ownership if shares are issued to former NZ Corporation shareholders who have perfected certain rights.
The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at http://www.sec.gov. Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.
SOURCE Lipid Sciences, Inc.
Web Site: http://www.lipidsciences.com
031203
PR031203
Copyright © 2003 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .